You know it's a slow news cycle when various media outlets stumble over themselves to report what every endo has known for years: long term use of Avandia in women with low bone density can contribute to bone thinning. Easily mitigated by treatment with an osteoporosis drug. Duh. And the Nature Medicine article simply identified the specific receptor the PPAR pathway targeted that caused the degeneration in mice, it did not discover the mechanism of degeneration. That was discovered a long time ago. Not one article suggested that there was a benefit to continuing Avandia or put the bone loss risk in context with blindness, kidney loss, amputation as a result of diabetes.
Here are some sources in case journalists are interested in reading....
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
[Endocrinology. 2005]
Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
[J Bone Miner Res. 2005]
Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
[Bone. 2006]
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
[Bone. 2006]
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
[J Endocrinol. 2004]
Here are some sources in case journalists are interested in reading....
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
[Endocrinology. 2005]
Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
[J Bone Miner Res. 2005]
Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
[Bone. 2006]
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
[Bone. 2006]
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
[J Endocrinol. 2004]
